

Mei-Yin C Polley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7231595/publications.pdf>

Version: 2024-02-01

29
papers

1,827
citations

516710
16
h-index

580821
25
g-index

29
all docs

29
docs citations

29
times ranked

2951
citing authors

#	ARTICLE	IF	CITATIONS
1	An International Ki67 Reproducibility Study. Journal of the National Cancer Institute, 2013, 105, 1897-1906.	6.3	498
2	Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. Journal of the National Cancer Institute, 2021, 113, 808-819.	6.3	319
3	An international study to increase concordance in Ki67 scoring. Modern Pathology, 2015, 28, 778-786.	5.5	195
4	Statistical and Practical Considerations for Clinical Evaluation of Predictive Biomarkers. Journal of the National Cancer Institute, 2013, 105, 1677-1683.	6.3	118
5	Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Research and Treatment, 2018, 167, 89-99.	2.5	74
6	Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. Journal of Clinical Oncology, 2020, 38, 4184-4193.	1.6	74
7	Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. Blood, 2020, 135, 2224-2234.	1.4	62
8	CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2022, 40, 1323-1334.	1.6	62
9	Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. Journal of Clinical Oncology, 2019, 37, 2338-2348.	1.6	56
10	Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. Npj Breast Cancer, 2019, 5, 34.	5.2	55
11	Leveraging external data in the design and analysis of clinical trials in neuro-oncology. Lancet Oncology, The, 2021, 22, e456-e465.	10.7	53
12	Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients. Npj Breast Cancer, 2020, 6, 4.	5.2	49
13	Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry. Blood Cancer Journal, 2018, 8, 96.	6.2	47
14	Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1“positive Triple-negative Breast Cancer. Clinical Cancer Research, 2021, 27, 5628-5637.	7.0	32
15	Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. Journal of Clinical Oncology, 2022, 40, 2539-2545.	1.6	23
16	A clinical calculator to predict disease outcomes in women with triple-negative breast cancer. Breast Cancer Research and Treatment, 2021, 185, 557-566.	2.5	19
17	Statistical Considerations in the Evaluation of Continuous Biomarkers. Journal of Nuclear Medicine, 2021, 62, 605-611.	5.0	19
18	Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study. Modern Pathology, 2022, 35, 1362-1369.	5.5	18

#	ARTICLE	IF	CITATIONS
19	Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era. Leukemia and Lymphoma, 2020, 61, 298-308.	1.3	15
20	A Validated T Cell Radiomics Score Is Associated With Clinical Outcomes Following Multisite SBRT and Pembrolizumab. International Journal of Radiation Oncology Biology Physics, 2020, 108, 189-195.	0.8	15
21	Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations. Blood Cancer Journal, 2019, 9, 20.	6.2	10
22	A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy. Breast Cancer Research and Treatment, 2021, 189, 15-23.	2.5	6
23	The CCND1 c.870G risk allele is enriched in individuals of African ancestry with plasma cell dyscrasias. Blood Cancer Journal, 2020, 10, 39.	6.2	4
24	Power estimation in biomarker studies where events are already observed. Clinical Trials, 2017, 14, 621-628.	1.6	3
25	Bleomycin Use in the Treatment of Hodgkin Lymphoma (HL): Toxicity and Outcomes in the Modern Era. Blood, 2019, 134, 4038-4038.	1.4	1
26	Two-Stage Adaptive Design for Prognostic Biomarker Signatures With a Survival Endpoint. Statistics in Biopharmaceutical Research, 2020, , 1-10.	0.8	0
27	On the Quest of Risk Stratification in HER2-Positive Breast Cancer. Journal of the National Cancer Institute, 2021, , .	6.3	0
28	Genomic Abnormalities Among African Individuals with Monoclonal Gammopathies Using Calculated Ancestry. Blood, 2018, 132, 4458-4458.	1.4	0
29	The CCND1 870G Risk Allele Is Enriched in African Individuals with Plasma Cell Dyscrasias. Blood, 2019, 134, 4362-4362.	1.4	0